Kodiak Sciences Past Earnings Performance
Past criteria checks 0/6
Kodiak Sciences's earnings have been declining at an average annual rate of -21.4%, while the Biotechs industry saw earnings growing at 13.2% annually.
Key information
-21.4%
Earnings growth rate
-18.2%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | n/a |
| Return on equity | -103.4% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Kodiak Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -192 | 63 | 141 |
| 30 Jun 24 | 0 | -198 | 67 | 145 |
| 31 Mar 24 | 0 | -233 | 69 | 180 |
| 31 Dec 23 | 0 | -260 | 71 | 206 |
| 30 Sep 23 | 0 | -271 | 72 | 216 |
| 30 Jun 23 | 0 | -298 | 72 | 241 |
| 31 Mar 23 | 0 | -309 | 72 | 248 |
| 31 Dec 22 | 0 | -334 | 74 | 268 |
| 30 Sep 22 | 0 | -357 | 73 | 287 |
| 30 Jun 22 | 0 | -347 | 67 | 282 |
| 31 Mar 22 | 0 | -312 | 59 | 253 |
| 31 Dec 21 | 0 | -267 | 50 | 217 |
| 30 Sep 21 | 0 | -220 | 42 | 179 |
| 30 Jun 21 | 0 | -189 | 38 | 152 |
| 31 Mar 21 | 0 | -159 | 33 | 128 |
| 31 Dec 20 | 0 | -133 | 29 | 107 |
| 30 Sep 20 | 0 | -102 | 22 | 83 |
| 30 Jun 20 | 0 | -78 | 18 | 64 |
| 31 Mar 20 | 0 | -64 | 15 | 52 |
| 31 Dec 19 | 0 | -47 | 12 | 38 |
| 30 Sep 19 | 0 | -46 | 11 | 32 |
| 30 Jun 19 | 0 | -44 | 10 | 26 |
| 31 Mar 19 | 0 | -41 | 8 | 21 |
| 31 Dec 18 | 0 | -41 | 8 | 19 |
| 30 Sep 18 | 0 | -38 | 6 | 21 |
| 30 Jun 18 | 0 | -32 | 5 | 19 |
| 31 Mar 18 | 0 | -31 | 5 | 21 |
| 31 Dec 17 | 0 | -28 | 3 | 22 |
Quality Earnings: KOD * is currently unprofitable.
Growing Profit Margin: KOD * is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KOD * is unprofitable, and losses have increased over the past 5 years at a rate of 21.4% per year.
Accelerating Growth: Unable to compare KOD *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KOD * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: KOD * has a negative Return on Equity (-103.37%), as it is currently unprofitable.